Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SkinBioTherapeuticsLSE:SBTX -2.13%39 Days Payable is 110.72 as of Dec. 2025, which is 80% below its 10-year median of 544.74. GuruFocus rates LSE:SBTX with a GF Score™ of 39/100 and a GF Value™ of £0.66 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 703 Biotechnology companies, SkinBioTherapeutics ranks worse than 50.36% on this metric.
The historical rank and industry rank for SkinBioTherapeutics's Days Payable or its related term are showing as below:
LSE:SBTX'
s Days Payable Range Over the Past 10 Years
Min: 81.45 Med: 544.74 Max: 1036.76
Current: 112.61
During the past 10 years, SkinBioTherapeutics's highest Days Payable was 1036.76. The lowest was 81.45. And the median was 544.74.
LSE:SBTX's Days Payable is ranked worse than 50.36% of 703
companies
in the Biotechnology industry
Industry Median: 112.84
vs LSE:SBTX: 112.61
SkinBioTherapeutics's Days Payable
declined
from Dec. 2024 (131.07) to Dec. 2025 (110.72).
It may suggest that SkinBioTherapeuticsaccelerated paying its suppliers.
The historical data trend for SkinBioTherapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SBTX vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, SkinBioTherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SkinBioTherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SkinBioTherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where SkinBioTherapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SkinBioTherapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SkinBioTherapeutics (LSE:SBTX) has a Days Payable of 110.72 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SkinBioTherapeutics and its competitors. This is 80% below median its historical median of 544.74. Over the past decade, SkinBioTherapeutics' Days Payable has ranged from 81.45 to 1,036.76. According to the industry distribution chart, SkinBioTherapeutics ranks #354 out of 703 companies in the Biotechnology industry, placing it in the top 50.4%.
Is SkinBioTherapeutics' Days Payable too high?
SkinBioTherapeutics' current Days Payable of 110.72 is 80% below median its 10-year median of 544.74. Over the past 10 years, this metric has ranged from a low of 81.45 to a high of 1,036.76. The Biotechnology industry median Days Payable is 112.84. SkinBioTherapeutics' value of 110.72 is 1.9% below this industry median. Based on the distribution chart, SkinBioTherapeutics ranks #354 out of 703 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SkinBioTherapeutics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SkinBioTherapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SkinBioTherapeutics ranks #354 out of 703 companies for Days Payable. This places SkinBioTherapeutics in the lower half of its industry. The industry median Days Payable is 112.84. SkinBioTherapeutics' value of 110.72 is 1.9% below this benchmark. Historically, SkinBioTherapeutics' own Days Payable has ranged from 81.45 to 1,036.76 over the past decade. While the company's 10-year median is 544.74 vs. the industry median of 112.84, SkinBioTherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SkinBioTherapeutics's current Days Payable of 110.72 is 1.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SkinBioTherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SkinBioTherapeutics's current Days Payable is 110.72, which is 80% below median its own 10-year median of 544.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SkinBioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, SkinBioTherapeutics (LSE:SBTX) is currently considered Possible Value Trap. The stock's GF Value™ is £0.66, compared to a current price of £0.12 — trading 82.6% below its estimated fair value. The current Days Payable is 110.72, which is 80% below median its 10-year median of 544.74 and 1.9% below the Biotechnology industry median of 112.84. SkinBioTherapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SkinBioTherapeutics (LSE:SBTX), the current Days Payable is 110.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SkinBioTherapeutics (LSE:SBTX) Overvalued in 2026?
Based on GuruFocus' analysis, SkinBioTherapeutics stock appears to be undervalued.
The current stock price of £0.12 is trading 82.6% below its estimated GF Value™ of £0.66.
GuruFocus considers SkinBioTherapeutics to be Possible Value Trap.
Key valuation signals for LSE:SBTX:
Days Payable: 110.72 (80% below median its 10-year median of 544.74)
GF Value™: £0.66 vs. price of £0.12 (82.6% below fair value)
Industry Position: 1.9% below the Biotechnology median (#354 of 703)
No single metric tells the full story. See the LSE:SBTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
39GF Score
Get the complete analysis for LSE:SBTX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SBTX has been successfully added to your 
